Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metabolic Divergence Between MASLD and Metabolic Syndrome: Distinct Clinical Phenotypes and Risk Stratification Implications.

Liver international : official journal of the International Association for the Study of the Liver - 1 Sept 2025

Ramírez-Mejía Mariana M, Barbalho Sandra M, Ponciano-Rodríguez Guadalupe, Eslam Mohammed, George Jacob, Zheng Ming-Hua, Méndez-Sánchez Nahum

Abstract excerpt

BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the leading cause of chronic liver disease worldwide. Metabolic syndrome (MetS) has traditionally been used as an indicator to define metabolic dysfunction, but it may not fully reflect the risk spectrum of MASLD, underscoring the need to better understand its clinical heterogeneity. The aim of this study was to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cluster Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatty Liver

Share to Metabolic Syndrome

Share to Phenotype

Share to Risk Assessment

Share to Risk Factors

Source

Identifiers

PMID: 40851501
DOI: 10.1111/liv.70305

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metabolic Divergence Between MASLD and Metabolic Syndrome: Distinct Clinical Phenotypes and Risk Stratification Implications.PMID 40851501Read ↗

Cardiometabolic phenotype linked to fibrosis and mortality in metabolic dysfunction-associated steatotic liver disease.Semantic proximity Read ↗

Novel subtypes of metabolic associated steatotic liver disease linked to clinical outcomes: implications for precision medicine.Semantic proximity Read ↗

Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome AnalysisSemantic proximity Read ↗

Data-driven cluster analysis identifies distinct types of cardiovascular-kidney-metabolic syndromeSemantic proximity Read ↗

Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.Semantic proximity Read ↗

Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtypingSemantic proximity Read ↗

Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision makingSemantic proximity Read ↗

Mapping the genomic landscape of MASLD: A framework for molecular subtyping and precision hepatology.Semantic proximity Read ↗

Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated alcohol‑related liver disease represent distinct clinical phenotypes and fibrosis risks: insights from a population-based Polish cohort.Semantic proximity Read ↗

[Precise clinical classification of metabolic associated fatty liver disease].Semantic proximity Read ↗

Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease.Semantic proximity Read ↗

Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.